Interleukin-3 (IL-3) and granulocyte/macrophage-colony-stimulating factor (GM-CSF) are responsible for maintaining survival and stimulating growth of early dormant hematopoietic progenitor cells (HPC 
Introduction
A variety of normal tissues are characterized by high rates of cell turnover in which mature cells are consumed or die. These cells are continually replaced by others that are derived from primitive, undifferentiated cells. Cell division represents the most important inherent source of increased risk of mutation and chromosomal aberrations throughout life, and a number of agents whose major biological effect is to induce cell proliferation are major risk factors for specific human cancers (1) . Therefore, it is not surprising that cell maturation and proliferation in such tissues is highly ordered so that replication of cells with the greatest potential for neoplastic transformation is tightly controlled, and so that cells undergoing the most rapid turnover are committed to terminal differentiation or apoptosis (2) . Normal hematopoiesis is probably the ultimate example of a tightly regulated process in which cell survival, differentiation, and proliferation are inextricably linked and controlled by multiple This paper was presented at Benzene '95: An International Conference on the Toxicity, Carcinogenesis, and Epidemiology of Benzene held [17] [18] [19] [20] June 1995 in Piscataway, New Jersey. Manuscript received 16 January 1996; manuscript accepted 14 June 1996. growth factors or cytokines that collaborate to regulate hematopoiesis (3) .
The results of a number of studies utilizing a variety of different systems support the observation that altered response to hematopoietic cytokines, specifically granulocyte/macrophage-colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3), feature prominently in early events in the leukemogenic process. Enhanced expression of GM-CSF or IL-3 results in profound myelodysplastic changes (4) (5) (6) , and altered clonogenic response to GM-CSF is a frequent early observation in the development of acute myelogenous leukemia (AML) (7, 8) . Moreover, inhalation exposure of mice to benzene enhances clonogenic response to GM-CSF (9, 10) , and chronic exposure to high concentrations induces a persistent myeloproliferative disorder (10, 11) . These specific alterations are most likely due to hydroquinone (HQ), which selectively enhances clonogenic response to GM-CSF in murine bone marrow cells (12, 13) . Our work has focused on understanding the relationship between altered response of primitive bone marrow cells to cytokines involved in proliferation and survival and early events in leukemogenesis. These studies have revealed that the potential to act synergistically with GM-CSF to induce a clonogenic response in primitive HPC is a characteristic shared by a variety of leukemogenic agents (12, 13) . Pretreatment of murine bone marrow cells with these agents or their metabolites in vitro results in increased numbers of HPC dividing and forming colonies in response to GM-CSF but not IL-3. The present studies were designed to evaluate potential molecular mechanisms associated with altered cytokine response in early HPC in murine bone marrow and to extend our initial observations in mice to human bone marrow cells.
Materials and Methods
Reagents. Murine recombinant (r)GM-CSF (5 x 107 U/mg) and human rGM-CSF (1.25 x 107 U/mg), recombinant stem cell factor (SCF) ( (12) . Briefly, animals were killed by cervical dislocation and bone marrow was flushed from femora with PBS containing 1% BSA using a 5-ml syringe with a 22-gauge needle. A single cell suspension was obtained using a Pasteur pipet, which was then purified over Lympholyte-M. The CFUAssay. The CFU assay was performed as previously described (12) . Briefly, bone marrow cells were plated in 35-mm culture dishes at a concentration of 1 to 5 x 104 cells/ml in 1 ml modified Iscove's medium containing 10 to 20% FBS, 100 mg/ml streptomycin, 100 U/ml penicillin, 2 mM L-glutamine, 50 mM 2-mercaptoethanol, 1 .2% (wt/vol) methyl cellulose, and recombinant cytokines. Each cytokine was used at concentrations experimentally determined to produce maximal colony formation. All cultures were maintained at 37°C in 5% CO2. Colonies (14) . Binding assays were carried out using a phthalate oil separation method (15) as performed by Park et al. (14) , and association/dissociation kinetics were analyzed as previously described (16, 17) . Specific activity of each preparation was determined by selfdisplacement analysis (18 (19) . The CD34+ cell population contains all clonogenic cells identified in human bone marrow, including both long-term and short-term repopulating cells (20) and is markedly enriched for primitive HPC. Using this method, the purity of CD34+ routinely obtained from unrelated volunteers is greater than 91% and often approaches 99% ( Table 1) . The flow cytometric distribution of the CD34 marker in purified human bone marrow cells is illustrated in Figure 1 .
Effects of HQ Pretreatment on Human Bone Marrow Cells
Similar to previously reported results in murine bone marrow, HPC normally unresponsive to rGM-CSF are induced by HQ pretreatment to selectively respond to human rGM-CSF and not human rIL-3 ( Figure 2) . HQ pretreatment at 10-6 M induces a 291% increase in clonal response to rGM-CSF. Similar to results obtained in mice, HQ pretreatment of human HPC does not mimic SCF, since cells grown in the presence of rGM-CSF + rSCF are also recruited to respond by HQ pretreatment independent of rSCF.
Studies on the Role ofAltered GM-CSF Receptor Expression
A series of experiments was conducted to evaluate potential mechanisms associated with HQ-induced enhancement of clonogenic response in murine bone marrow cells. Previous experiments utilizing murine HPC essentially depleted of stromal, and lineage-committed bone marrow cells suggest that the observed synergistic response to rGM-CSF represents an intrinsic effect on responding HPC and is independent of altered production of cytokines by accessory cell populations (12, 13) . Because HQ-induced synergism is specific for GM-CSF, the possibility that HQ pretreatment results in altered GM-CSF receptor expression was evaluated. We measured 280 high-and 1700 low-affinity sites, respectively, for an enriched population of murine HPC that compares favorably with previously reported ranges for high-(10-100) and low-(300-500) affinity sites/cell in unfractionated bone marrow cells (21) . Nonspecific binding occurred linearly with increasing concentration of 1251-rGM-CSF and was in every case < 3% of the total disintegrations per minute added. The results of these experiments presented in Figure 3 indicate that HQ pretreatment has no detectable influence on high-affinity GM-CSF receptors, suggesting that the increased recruitment of GM-CSF responsive myeloid progenitor cells by HQ pretreatment is not the result of either an up-or a down-regulation of GM-CSF receptors or changes in receptor-ligand affinity.
Discussion
We have demonstrated that clonogenic response in selected populations of HPC is subject to chemical influence and that chemical/drug pretreatment can synergize with growth factors, resulting in clonogenic recruitment of subpopulations of murine and human HPC (12, 13) . Hematopoiesis is characterized by a hierarchy of progenitor cell types with specific genetic repertoires and phenotypic characteristics that define their capacity with respect to survival, self-renewal proliferation, and differentiation. It is generally recognized that proliferation of committed multi-or single-lineage HPC is controlled by multiple growth factors with overlapping specificity, and a variety of positive and negative control mechanisms have been described that are required to maintain cell homeostasis in this system (22) . It is likely that altered clonogenic response to cytokines involves alterations in molecular signals associated with cell survival, proliferation or differentiation. Nevertheless, it is not known whether the cellular transduction mechanism(s) governing these processes are subject to individual environmental manipulation. For HQ, synergism appears to be due to an intrinsic increase of additional clones of cells that are responsive to the growth factor rather than to changes in the rate of cell proliferation (12) . that HQ is causing a release of IL-3 (data not shown). The most plausible explanation based on available data is that HQ activates a mechanism involving one or more secondary signals that are not sufficient to induce HPC into cycle but will synergize with GM-CSF to do so. In a rapidly dividing tissue such as bone marrow in which control of stem and progenitor cell proliferation commands a high priority, changes in proliferation or survival may predispose susceptible target cells to replication-dependent damage and subsequent neoplastic transformation. Issues remaining to be addressed include the elucidation of the molecular mechanism(s) of enhanced cytokine response and clarification of the impact of increasing, by as much as 2-fold, the size of the replicating cell population that is potentially targeted in the development of AML. Characterization of the respective roles of proliferation and differentiation in the regulation of HPC will provide a biological basis for improving predictions of the risk of leukemogenesis secondary to benzene exposure.
